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Stereotactic body radiotherapy (SBRT) is attracting 
substantial interest as a treatment option for selected 
patients with metastatic disease. It is reasonable to take a 
step back and take a look at where the field is now and what 
we can expect from this intervention. This presentation will 
focus on a number of contemporary clinical issues, including: 
what can be expected from SBRT at various anatomical sites; 
definitions of oligo-metastatic disease and their limitations; 
defining treatment goals in metastatic disease; lessons from 
published outcome data; a pragmatic approach to decision-
making in the clinic; is radiation technology driving the 
agenda? and; gathering evidence for the future. 
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Patients with oligometastases from colo-rectal carcinoma 
(CRC) are often considered as candidates for surgical 
resection, radiofrequency ablation and SBRT and CRC often 
metastasize to the abdominal organs, especially to the liver. 
Therefore, abdominal oligo-metastases are often treated 
with SBRT. A relative large number of publications 
demonstrate outcome after SBRT for liver metastases that 
are almost as good as for lung metastases. Local control rates 
in both lung and liver are most often in the range 70-90% and 
survival rates are depending on tumor type and the selection 
of the patients. There are only few publications on SBRT of 
abdominal, non-liver oligometastases, but the few available 
publications indicate favourable local control as well for 
these patients. Most publications on SBRT for abdominal 
targets report a low risk of morbidity, but there are reports 
of relatively severe morbidity related to irradiation of the 
liver and the bowel, most often in terms of severe mucositis 
or intestinal ulceration. Treatment of abdominal targets is 
complex due to the multiple organs at risk. Treatment 
planning is based on a snapshot of the anatomy on a 
treatment planning CT-scan. 4DCT takes the intrafraction 
motion motion of the target into account, but we usually do 
not take the motion of bowel structures into account. CBCT is 
used to correct for set-up errors of the target, but organs at 
risk are less often considered. This may lead to unintended 
high doses to the organs at risk and side effects that were not 
expected from the treatment planning. 
 
Symposium: Head and neck: state-of-the-art and directions 
for future research  
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Recent progress has been made in oncology with new drug 
targeting immune system. Ipilimumab which targets CTLA-4 
has been the first one approved in melanoma. Another way to 
block the deleterious cascade of T-lymphocyte inhibition is to 
block an extracellular target, namely Programmed Death 
Receptor-1 (PD-1). PD-1 is a cell surface receptor expressed 
by T cells, B cells, and myeloid cells, and member of the 
CD28 family involved in T cell regulation. PD-1 pathway is 
activated by receptor binding to ligands (PD-L1 or PD-L2) and 
its physiological role is to prevent uncontrolled immune 
activation during chronic infection or inflammation. In 
cancer, activation of PD-1 pathway can suppress antitumor 
immunity. In mouse models, antibodies blocking PD-1/PD-L1 
interaction lead to tumor rejection. In clinical trials, 
targeting PD-1 pathway using human monoclonal antibody 
such as nivolumab, which blocks binding of PD-1 to PD-L1 and 
PD-L2, showed promising results in metastatic solid tumors 
with durability of objective responses, and sustained overall 
survival (Topalian and al, NEJM 2012). Phase I studies showed 
a potential better safety profile of anti-PD-1/PD-L1 agents in 
comparison with ipilimumab. Following, anti-PD-1/PD-L1 
drugs have been developed at a phenomenal speed, taking 
just three years from the first clinical trials to approval. At 
now, anti-PD-1 nivolumab and pembrolizumab are approved 
in melanoma and NSLCC... There is a strong rationale for 
using anti-PD-1/PD-L1 agents in HNSCC. Tumor-infiltrating 
lymphocytes (TILs) which are required for PD-1 blockade, and 
PD-L1 expression are present in HPV+ and HPV negative 
HNSCC. There is a correlation between infiltration by CD8 
cells and response to CRT, and between PD-L1 expression and 
survival. The high number of specific mutations observed in 
HNSCC could be a mechanism of immunogenicity. Results of 
phase I studies testing anti-PD-1/PD-L1 agents in HNSCC 
patients have been recently reported with promising results 
in terms of efficacy with prolonged responses. During ASCO 
2014 meeting, Seiwert et al. presented first results of a 
phase Ib study of pembrolizumab in recurrent/metastatic 
(R/M) HNSCC patients. Patients with ≥1% PD -L1 
immunohistochemistry expression in tumor cells or stroma 
were enrolled in the study. The anti-tumor effect was 
observed both in patients with HPV-positive and HPV-
negative tumors. The duration of these responses was 
impressive, some already lasting over one year (Seiwert TY et 
al., ASCO 2014, CSS 6011). Updated data on a expanded 
cohort have been presented at last ASCO 2015 meeting. 132 
(81 HPV+) R/M HNSCC patients were treated with 
prembrolizumab 200 mg Q3W regardless of HPV or PD-L1 
status. 78% received at least one line of chemotherapy. 
Tolerance was good (9.8% of grade 3-5 adverse events). 
Objective response rate was 25%, stable disease rate was 25% 
with long-lasting responses (Seiwert TY, et al. J Clin Oncol. 
2015;33(suppl): LBA6008). First results of a phase I study 
evaluating the safety and efficacy of an anti-PD-L1 agent, 
durvalumab (MEDI4736), have been presented at ESMO 2014 
congress (M. Fury M et al., abstr 988PD, ESMO 2014). 
MEDI4736 is a human IgG1 mAb, engineered to prevent ADCC 
activity, that blocks PD-L1 binding to PD-1 and CD-80. 50 pts 
with HNSCC, with median 3 prior treatments received median 
3 doses of MEDI4736 10 mg/kg q2w. Treatment-related 
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adverse events were observed in 39% of pts; most frequently 
nausea (6%), diarrhea, dizziness, and rash (4% each). 
Dyspnea, syncope, raised GGT and sepsis (each 5%) were the 
most common grade ≥3  AEs. Among 29 evaluable HNSCC pts 
for efficacy, 4 pts had a partial response. Numerous anti-PD-
1/PD-L1 agents are currently tested in HNSCC. First 
randomized trial with nivolumab vs standard of care in 
second line after platinum based first line therapy has just 
closed. Randomized trials testing pembrolizumab and 
durvalumab in first-line or second-line treatment for R/M 
HNSCC patients are ongoing. Beside evaluation of efficacy, 
these studies should help define the best population (HPV 
status, prior therapies) and more useful biomarkers than 
threshold of PD-L1 expression, to select patients who can 
benefit from these new agents. Flare-up reaction with 
increase of tumor volume and immune-related adverse 
events may occur: new guidelines are needed to define 
criteria of response, time to stop treatment and management 
of toxicities. Some patients may have a fast progression 
under monotherapy and mechanisms of resistance are 
unclear. New approaches combining anti-PD-L1/PD-1 agents 
and other immune-modulators, chemotherapy and 
radiotherapy are currently explored. Abscopal effect related 
to anti-PD-L1/PD-1 agents seems promising. For locally 
advanced HNSCC, trials testing combinations with anti-PD-
L1/PD-1 agents in induction regimen and concurrent CRT are 
ongoing. The story of immunotherapy as a new paradigm in 
HNSCC is just beginning… 
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Stereotactic radiation of small brain targets provides high 
spatial resolution and accuracy for positioning of patient and 
radiation fields, almost on submillimeter ranges. This is not 
matched by equally sharp dose gradients, since finite source 
size, collimator design limitations and transport of electrons 
in the irradiated tissue all diffuses the dose. Not surprisingly, 
the dose prescriptions evolving for small brain tumors aimed 
for a specified dose to the target periphery, accepting 
whatever resulting dose to the target center. A kind of 
standard evolved aiming for a ratio of approximately 65% 
relative dose at the periphery versus the maximum target 
center dose (or 154% center-to-periphery ratio). This dose 
heterogeneity was considered favorable, as to more 
effectively treat presumably hypoxic cells at the tumor 
center. The stereotactic treatment methodology for brain 
treatments were in the early 1990s transferred to radiation 
of liver metastasis. Through use of stereotactic body frame 
high target positioning reproducibility was achieved, and 
similar dose prescriptions of heterogeneous dose were 
applied, with a center-to-periphery dose ratio of 
approximately 154%. Soon the technique was also applied to 
peripheral lung tumors.  
Following the development of 3D treatment planning systems 
in the late 1980s, ICRU responded to the need for consistent 
handling of geometrical uncertainties and launched in 1993 
the ICRU 50 report recommending the use of GTV, CTV and 
PTV to capture the uncertainties. Specifically, the role of 
PTV was to “ensure that the prescribed dose is actually 
absorbed in the CTV”. The normal use of the PTV is to plan a 
homogenous dose to its interior, through which it is assumed 
that the CTV gets the same dose as it is located in the PTV. 
This requires the dose inside the PTV to be both 
homogeneous and robust with respect to movements 
involving heterogeneities. The PTV concept was applied also 
for extracranial stereotactic body treatments, often 
inheriting a high center-to-periphery prescription. Dose 
calculations at the time used “class a” algorithms that not 
account for dose variations due to a varying level of lateral 
charged particle equilibrium caused by low density regions. 
Most so called pencil beam algorithms belong to this, class a, 
category. Accurate dose calculations can now be achieved 
with “class b” algorithms such as Monte Carlo, Collapsed 
Cone or Grid based Boltzmann equation solvers. However, for 
any algorithm that would calculate the dose physically 
correct, the resulting dose for the PTV is not representative 
for the CTV when the margin around the latter contains a 
lower density medium. Hence, the straight forward 
application of PTV based treated planning together with 
heterogeneous prescriptions principles (originally inherited 
from intracranial treatments), has created a confused 
situation with large uncertainties with respect to the actually 
delivered doses.  
A robust dosimetry can be achieved by realizing that the dose 
to a CTV surrounded by a low density medium will be 
independent of movements as long as it is exposed to a 
uniform fluence. Given that a near homogeneous fluence 
cover the PTV, dose prescriptions can then be done directly 
to the CTV based on a dose calculation with a “class b” 
algorithm (MC, CC or equivalent). As long as the movements 
of the CTV are kept well inside a PTV with a homogeneous 
fluence, the dose delivered to the CTV will be much closer to 
the prescribed dose, thus providing robust dose specification 
for small tumors. However, tools for optimization of uniform 
fluence are presently not provided in clinical TPS. Luckily, 
several workarounds exists that can “cheat” the optimization 
of homogenous dose to instead yield a effectively 
homogeneous fluence. From a pure physics point of view, this 
can be achieved by incapacitating the lateral spread of 
energy from the rays of the primary beam. In class a 
algorithms of the pencil beam kind, this can be implemented 
by changing the pencil beam parameter controlling the 
lateral spread. In point kernel algorithms such as CC, similar 
manipulation of kernel data can be done. In essence, in most 
algorithms fluence is a precursor for dose providing 
opportunities to access it. Alternatively, the density of the 
PTV can be set to a high value that shortens the electron 
transport distance enough to make the dose more fluence 
like.  
In summary, a robust small lung tumor dose can be 
implemented through a planning process in which the PTV is 
determined by the common practice addition of a setup 
margin to a MIP projections ITV, but replacing the common 
practice dose calculations by a fluence optimization followed 
by a class b dose calculation with the CC (or similar) 
algorithm, using absolute dose prescriptions to the CTV 
rather than the PTV. For a test series of 5 patients this 
procedure reduced the difference between prescribed and 
delivered dose to the CTV from 30% to 8% in D98, with a 
similar reduction for D02. 
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The current practice of cranial and extra-cranial stereotactic 
radiotherapy is in many ways influenced by Gamma-Knife 
Radiosurgery (GN-RS). It has been a key component of GN-RS 
to treat the target volumes without any safety margins (GTV 
= PTV) and to use inhomogeneous dose profiles within the 
target volume. The dose was most frequently prescribed to a 
low isodose e.g. 50% meaning that substantially higher doses 
are delivered to the central part of the tumor.  
This practice of dose prescription to a low target 
encompassing isodose line has been adopted in extra-cranial 
stereotactic radiotherapy (Stereotactic Body Radiotherapy 
